# Who are AbbVie's customers? Who does AbbVie earn revenue from?
Canonical: https://valuechain.wiki/abbvie · Facet: customers · Updated: 2026-10-09T16:09:06.345+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: AbbVie's confirmed revenue counterparties include Cencora, Inc., Cardinal Health, Inc., Celltrion plus 3 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 6 revenue edges, backed by 7 dated sources, 4 of them primary filings (as of 2026-10-09).

### 면역질환 시장 (스카이리치·린버크) (high)
- metric: Amount $25.9B · FY2025 스카이리치+린버크 · Skyrizi $17.56B, Rinvoq $8.30B, Humira $4.54B
- note: Top revenue driver. Skyrizi $17.6B (+50%) and Rinvoq $8.3B (+39%) together reached $25.9B, offsetting Humira's fall to $4.5B (-49%) under direct biosimilar competition and lifting total revenue to a record $61.2B.
- [confirms] SEC EDGAR (AbbVie 10-Q) (EN, filing, published 2026-08-03) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm: ""Total net revenues $ 16,990 $ 15,423 ... $ 31,992 $ 28,766"; "Skyrizi ... Total $ 5,505 $ 4,423 $ 9,988 $ 7,848"; "Rinvoq ... Total $ 2,525 $ 2,028 $ 4,644 $ 3,746"; "Humira ... Total $ 756 $ 1,180" (Q2 2026, Q2 2025, H1 2026, H1 2025; $ millions)"
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: ""Skyrizi Total $17,562 ... Rinvoq Total $8,304 ... Humira Total $4,540 ... Net revenues for Humira decreased 49% in 2025 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity.""
- [confirms] TIKR (EN, analysis, published 2026-02-01) https://www.tikr.com/blog/abbvie-posts-record-61b-revenue-as-skyrizi-and-rinvoq-surge-past-peak-humira-sales: "Skyrizi+Rinvoq $25.8B vs Humira $4.5B; record $61.1B."
- [confirms] TIKR (EN, analysis, published 2026-02-01) https://www.tikr.com/blog/abbvie-hits-31-billion-in-skyrizi-and-rinvoq-sales: "Skyrizi and Rinvoq delivered a combined $25.9 billion in 2025, exceeding AbbVie's 2027 long-term guidance more than two years early."
- [confirms] KPANews (KO, news, published 2025-11-05) https://www.kpanews.co.kr/article/show.asp?category=D&idx=254488: "Skyrizi and Rinvoq's combined quarterly sales surpassed Humira's peak, marking AbbVie's entry into the post-Humira era."

### 신경·미용 시장 (보톡스·브레일라·유브렐비) (high)
- metric: Amount $3.8B · FY2025 Botox Therapeutic · Vraylar $3.62B, Botox Ther. $3.77B, Ubrelvy $1.27B, Botox Cosmetic $2.60B
- note: Second growth pillar after immunology. Vraylar $3.6B (+11%), Botox Therapeutic $3.8B (+15%), Ubrelvy $1.3B (+27%) and Qulipta $1.0B (+57%), plus aesthetic Botox Cosmetic $2.6B.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: ""Vraylar Total $3,621 ... Botox Therapeutic Total $3,769 ... Ubrelvy Total $1,271 ... Qulipta Total $1,036 ... Aesthetics Botox Cosmetic Total $2,602""
- [confirms] KPANews (KO, news, published 2025-11-05) https://www.kpanews.co.kr/article/show.asp?category=D&idx=254488: "AbbVie posted record FY2025 revenue of $61.1 billion, up 8.6% year over year."

### 센코라 (high)  → /cencora.md
- note: AbbVie sells medicines to Cencora, a major U.S. wholesale customer, and said that three wholesalers including Cencora represented substantially all of its FY2025 U.S. pharmaceutical sales, but did not disclose Cencora's individual amount.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: "accounted for substantially all of AbbVie's pharmaceutical product sales in the United States"

### 카디널 헬스 (high)  → /cardinal-health.md
- note: AbbVie sells its U.S. pharmaceutical products through major wholesalers including Cardinal Health and does not disclose the amount or share attributable specifically to Cardinal Health.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: "three wholesale distributors (McKesson Corporation, Cardinal Health, Inc. and Cencora, Inc.)"

### 셀트리온 (mid)  → /celltrion.md
- metric: Amount $4.5B · FY2025 Humira · Humira 2023 $14.4B to 2025 $4.5B (-49% YoY)
- note: Celltrion's Humira biosimilar Yuflyma entered the U.S. under a patent settlement with AbbVie (royalty-bearing license). Biosimilar competition drove Humira revenue from $14.4B in 2023 to $4.5B in 2025.
- [mentions] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "Yuflyma (Humira biosimilar) launched in the US in July 2023 after a patent agreement with the originator, AbbVie."
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: ""Net revenues for Humira decreased 49% in 2025 primarily driven by continued impact of direct biosimilar competition following the loss of exclusivity ... AbbVie's immunology products compete with ... biosimilars.""
- [mentions] FSS DART (KO, filing, published 2025-03-18) https://dart.fss.or.kr/dsab007/main.do?option=corp&textCrpNm=%EC%85%80%ED%8A%B8%EB%A6%AC%EC%98%A8: "Celltrion supplies the adalimumab biosimilar Yuflyma in the U.S. and Europe, securing launch timing via a patent settlement with originator AbbVie."

### 종양 시장 (임브루비카·벤클렉스타·엘라히어) (mid)
- metric: Amount $2.9B · FY2025 Imbruvica · Imbruvica $2.87B, Venclexta $2.79B
- note: Imbruvica $2.9B (-14%, intensifying BTK competition) and Venclexta $2.8B (+8%) anchor oncology, with Elahere (ovarian-cancer ADC, acquired 2024) added as a new growth driver.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-20) https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm: ""Imbruvica Total $2,869 ... Venclexta Total $2,792 ... Elahere United States $607""

Reverse side: https://valuechain.wiki/abbvie/suppliers.md · Ripple: https://valuechain.wiki/abbvie/ripple.md

---
Full node: https://valuechain.wiki/abbvie.md · JSON: https://valuechain.wiki/abbvie.json